2019 American Transplant Congress
Association of Tacrolimus-Level Variance with De Novo DSA within the First 2 Years after Renal Transplantation
*Purpose: Patients that receive an HLA-mismatched kidney transplant (KT) have an increased likelihood to develop de novo DSA (dnDSA). Ideally, immunosuppression is properly adjusted and…2019 American Transplant Congress
Intravenous Immunoglobulin Significantly Reduces Bioavailability of Concomitantly Administered Anti-C5 Monoclonal Antibodies
*Purpose: Awareness of drug-drug interactions is critical in management of organ transplant recipients. However, there is little understanding of the possibility of biologic agents interfering…2019 American Transplant Congress
Tacrolimus Concentration/Dose Ratio is an Independent Predictor of Death-Censored Kidney Allograft Survival
*Purpose: Tacrolimus (Tac) remains the cornerstone of kidney transplantation immunosuppression. Its narrow therapeutic index demands therapeutic drug monitoring. The C/D ratio (Tac trough concentration /…2019 American Transplant Congress
Comparison of Initial Sirolimus (SRL) and Everolimus (EVR) Exposure Patterns in Kidney Transplant Recipients
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: Despite distinct pharmacokinetic properties, SRL and EVR bind to the same intracellular target protein, suggesting that equivalent blood concentrations may exert similar pharmacodynamic effect.*Methods:…2018 American Transplant Congress
High Tacrolimus Variability is Associated with Worse Outcomes in Pediatric Renal Transplant Recipients
Montefiore Medical Center, Bronx, NY.
Background: Subtherapeutic tacrolimus trough concentrations are associated with donor specific antibody (DSA), acute rejection and shortened graft survival. The role of intrapatient variability in tacrolimus…2018 American Transplant Congress
The Effect of Tacrolimus Trough Level and Intrapatient Variability on the Transplant Outcomes in Kidney Transplantation
Background: Tacrolimus (TAC) is the mainstay of immunosuppression for kidney transplantation (KT). Although TAC has a narrow therapeutic index, appropriate trough concentrations of TAC have…2018 American Transplant Congress
Assessment of Peak Levels and Metabolism Rates in African American (AA) and Non-AA Kidney Transplant Recipients (KTR) on Immediate-Release Tacrolimus (IR-tac)
Trough-to-daily dose (C/D) ratio has been used as a simple method for evaluation of IR-tac metabolism rate. Recent studies have shown that fast metabolizers defined…2018 American Transplant Congress
Once Daily CNI Administration Based on Pharmacodynamic Analysis for Preventing Viral Infection
BackgroundInfectious complications under immunosuppressive therapy are inevitable problems. Viral infection (include reactivation) occurs at a certain frequency even if immunosuppressive agents are totally adjusted by…2018 American Transplant Congress
Development of Optimal Simplified Equation for Estimation of Mycophenolic Acid Exposure Following Enteric-Coated Mycophenolate Sodium Administration in Chinese Renal Transplant Recipients
MyERA Study Group, Hangzhou, China.
Background: Limited sampling strategies (LSS) aids in overcoming the complexity of extensive PK sampling and supporting the calculation of mycophenolic acid (MPA) exposure. This study…2018 American Transplant Congress
Conversion from Twice Daily Immediate Release Tacrolimus to Once Daily Extended Release Tacrolimus (LCP-Tacro) in High Risk Kidney Transplant Recipients
Extended release once daily tacrolimus (LCP-Tacro) has demonstrated non inferiority to immediate release twice daily tacrolimus (IR-Tac) in kidney transplantation. These data are limited by…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 12
- Next Page »